NCT07300280PHASE1RecruitingAccepts Healthy Volunteers

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

Merck Sharp & Dohme LLC

Start Date

12/29/2025

Completion Date

10/21/2026

Summary

This goal of this trial is to learn about two medicines, enlicitide and rosuvastatin, in healthy people. Researchers will compare the amounts of enlicitide and rosuvastatin in a person's body over time, when they are given as separate medicines and when they are combined into one tablet.

Eligibility Criteria

Age Range: 18 years to 55 years

The main inclusion criteria include but are not limited to the following: * Is medically healthy with no clinically significant medical history * Is a non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to study entry Exclusion Criteria: * Is unable to refrain from or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to study entry * Is a female participant of childbearing potential

Interventions

DRUG

MK-0616A

DRUG

Enlicitide

DRUG

Rosuvastatin

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy

Locations

Celerion ( Site 0001)

Tempe, Arizona 85283

United States